We have been left behind by our peers (not only IMU) on the clinical development front. Pipeline in a product and Lag pure play obviously doesn't wash in the eyes of market.
AIPAC - agreed with poster 'China partner to develop' NSCLC and HNC - favourites to develop. But what's the end game - Merck would hold all ace cards and really don't need to over commit- supply agreements keep efti in trials possibly ad-infinitum? Where's the competitive tension?
Maybe I'm missing something here but not 'feeling the love' or advisory on strategic direction and comms have been p poor of late.
Also poor form imo for chairman to dismiss share price decline to purely geopolitical and other external issues.
I don't want fluff. Take responsibility.
IMM Price at posting:
27.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)